Immunic Inc IMUX

NAS: IMUX | ISIN: US4525EP1011 30/04/2025

0,990 USD (-22,65%)

(-22,65%) 30/04/2025

Grafiek Immunic Inc

Grafiek Immunic Inc

1 dag1d -22,65%
1 week1w -13,15%
1 maand1m -7,03%
3 maanden3m 2,56%
6 maanden6m -16,80%
1 jaar1j -23,84%
5 jaar5j -86,99%

Immunic Inc in het nieuws

Toon enkel gratis nieuws

30 april 2025 · Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial · Persbericht

10 april 2025 · Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments · Persbericht

9 april 2025 · Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments · Persbericht

1 april 2025 · Immunic, Inc. to Participate in Scientific and Industry Conferences in April · Persbericht

3 maart 2025 · Immunic to Participate in Scientific and Investor Conferences in March · Persbericht

4 september 2024 · Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome · Persbericht

28 augustus 2024 · Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September · Persbericht

8 augustus 2024 · Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

1 augustus 2024 · Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update · Persbericht

24 juli 2024 · Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec · Persbericht

Profiel Immunic Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

CEO: Daniel Vitt

Werknemers: 58

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe